2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1065

Acute Myocardial Infarction Variation Among U.S. Medicaid Recipients With Systemic Lupus Erythematosus By Race and Ethnicity, 2000-2006
Abstract Number: 2445

Acute Phase Reactant As a Marker Of Anti-Drug Antibody Formation In Ankylosing Spondylitis
Abstract Number: 561

Acyl-CoA Synthetase 1 Expression Is Increased In Murine Models Of Lupus As Well As In Human Systemic Lupus Erythematosus
Abstract Number: 483

Adalimumab and Methotrexate Pharmacokinetics Following Combination Therapy With Different Methotrexate Doses in Methotrexate and Biologic-Naïve Rheumatoid Arthritis Patients: Concerto Study
Abstract Number: 1467

Adalimumab In Combination With High and Low Dose-Methotrexate In Rheumatoid Arthritis Patients With Inadequate Response To Methotrexate: Pharmacokinetic Results From The Musica Study
Abstract Number: 2479

Adalimumab Significantly Reduces Inflammation In Active Ankylosing Spondylitis: An Ultrasound Study
Abstract Number: 2263

ADAMTS5 Is a Biomarker For The Efficacy Prediction Of Tocilizumab In Rheumatoid Arthritis
Abstract Number: 2091

Adaptation and Preliminary Testing of An Arthritis Walking Program to Reduce Joint Pain for Elderly Breast Cancer Survivors On Aromatase Inhibitor Therapy
Abstract Number: 1851

Adenosine 2A Receptor Promotes Collagen Production By Human Fibroblasts Via Smad2/3-Independent Pathways Involving Cyclic AMP and AKT
Abstract Number: 1830

Adenosine A_2A Receptor (A2AR) Diminishes Wear Particle (UHMWPE)-Mediated Osteolysis, Increases Bone Formation and Regulates Expression Of Axonal Guidance Proteins (AGP) By Macrophages, Osteoclasts (OC) and Osteoblasts (OB)
Abstract Number: 53

Adenosine A_2A Receptor As a Potential New Therapeutic Target For The Prevention/Treatment Of Osteoarthritis
Abstract Number: 935

Adenosine A2A Receptor Activates The Pro-Fibrotic Wnt / β-Catenin Signaling In Human Dermal Fibroblasts
Abstract Number: 1852

Adenosine A2A Receptors (A2AR) Promote Scarring By Repressing Mir-29a
Abstract Number: 2775

Adenosine A2b Receptor Agonist Bay60-6583 Restores Salivary Gland Function In a Mouse Model For Sjögren’s Syndrome
Abstract Number: 998

Adequacy Of Drug Coverage and Cost-Sharing For Medicare Beneficiaries With Rheumatoid Arthritis

« Previous Page
1
…
7
8
9
10
11
…
193
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].